MARC Record from harvard_bibliographic_metadata

LEADER: 02773cam a2200469 a 4500
001 012527207-3
005 20110706141310.0
008 100630s2010 nyua b 001 0 eng d
010 $a 2010929846
020 $a9781607618027
020 $a1607618028
035 0 $aocn646113643
040 $aBTCTA$beng$cBTCTA$dYDXCP$dSCB$dCUS$dMIA
060 4 $aQZ 170 A629 2010
090 $aRM340$b.A58 2010
245 00 $aAnticoagulants, antiplatelets, and thrombolytics /$cedited by Shaker A. Mousa.
250 $a2nd ed.
260 $aNew York, NY :$bHumana,$cc2010.
300 $axi, 316 p. :$bill. ;$c27 cm.
490 1 $aSpringer protocols
490 1 $aMethods in molecular biology,$x1064-3745 ;$v663
504 $aIncludes bibliographical references and index.
505 0 $aIn vitro methods of evaluating antithrombotics and thrombolytics / S.A. Mousa -- In vivo models for the evaluation of antithrombotics and thrombolytics / S.A. Mousa -- Heparin and low-molecular weight heparins in thrombosis and beyond / S.A. Mousa -- Laboratory methods and management of patients with heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Novel anticoagulant therapy: Principle and practice / S.A. Mousa -- Oral direct factor xa inhibitors, with special emphasis on rivaroxaban / S.A. Mousa -- Antiplatelet therapies: Drug interactions in the management of vascular disorders / S.A. Mousa -- Prasugrel: A novel platelet adp p2y(12) receptor antagonist / S.A. Mousa, W.P. Jeske and J. Fareed -- Antithrombotic effects of naturally derived products on coagulation and platelet function / S.A. Mousa.
505 8 $aAssessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis / A. Amirkhosravi ... [et al.] -- Adhesion molecules: Potential therapeutic and diagnostic implications / S.A. Mousa -- Pharmacogenomics in thrombosis / S.A. Mousa -- Diagnosis and management of sickle cell disorders / S.A. Mousa and M.H. Qari.
650 0 $aAnticoagulants (Medicine)
650 0 $aBlood platelets.
650 0 $aThrombolytic therapy.
650 0 $aFibrinolytic agents.
650 0 $aThrombolytic therapy$xMethods.
650 0 $aFibrinolytic agents$xTherapeutic use.
650 0 $aHeparin$xTherapeutic use.
650 12 $aThrombolytic Therapy$xmethods.
650 12 $aAnticoagulants$xtherapeutic use.
650 22 $aFibrinolytic Agents$xtherapeutic use.
650 22 $aHeparin$xtherapeutic use.
650 22 $aPlatelet Aggregation Inhibitors$xtherapeutic use.
650 22 $aThrombocytopenia$xdrug therapy.
700 1 $aMousa, Shaker A.
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$v663.
830 0 $aSpringer protocols.
988 $a20100713
906 $0OCLC